Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial
Uterine (endometrial) cancer
Phase 2 elacestrant oral SERD (estrogen receptor degrader) + everolimus mTOR inhibitor in ER+ endometrial cancer
This Phase 2, single-arm interventional study (ELAVERA) at UCLA/Jonsson Comprehensive Cancer Center evaluates elacestrant (an oral selective estrogen receptor degrader that binds ER and promotes receptor degradation)…
NCT07634601 Exploratory - New trial
Uterine (endometrial) cancer
Phase 1/2 MR‑guided adaptive IMRT (MR‑linac–based pelvic radiation) after surgery in high‑risk endometrial cancer
Rutgers Cancer Institute of New Jersey (Rutgers University) is running this Phase 1/2 feasibility study to test whether daily MRI‑guided, online adaptive pelvic IMRT can be delivered safely and consistently as…
NCT07643012 Exploratory - New trial Spotlight
Pancreatic cancer
Phase 2 VS-7375 oral KRAS G12D (ON/OFF) inhibitor ± EGFR antibody cetuximab in metastatic PDAC.
Verastem, Inc. is running TARGET-D 201 (NCT07644559), an open-label, multicenter Phase 2 study testing VS-7375—an oral, KRAS G12D–selective “ON/OFF” small-molecule inhibitor—given as monotherapy and in combination…
NCT07644559 Exploratory - New trial
Pancreatic cancer
Phase 1b samuraciclib trial tests CDK7 inhibitor transcription/cell-cycle blockade in basal PDAC
This single-institution, single-arm, open-label Phase 1b window-of-opportunity study evaluates whether samuraciclib (CT7001)—an oral small-molecule CDK7 inhibitor that disrupts transcriptional CDK activity and…
NCT07645651 Exploratory - New trial
Small cell lung cancer
Phase 1/2 DJI136 (LB2102) DLL3-targeted autologous CAR‑T for extensive-stage SCLC.
This Phase 1/2, open-label, non-randomized, multi-center study sponsored by Novartis Pharmaceuticals is testing DJI136 (also described as LB2102), an autologous CAR‑T cell therapy engineered to recognize DLL3 on…
NCT07564401 First-in-human - New trial Spotlight
Non-small cell lung cancer
Phase 3 setidegrasib (ASP3082) KRAS G12D–targeted protein degrader vs docetaxel
Astellas Pharma Global Development is running this randomized, open-label Phase 3 study comparing setidegrasib (ASP3082) with docetaxel in adults with locally advanced unresectable or metastatic NSCLC harboring KRAS…
NCT07566052 Registrational - New trial
Non-small cell lung cancer
Phase 2 olomorasib KRAS G12C covalent inhibitor + pembrolizumab PD‑1 blockade in 1L NSCLC.
This UNC Lineberger Comprehensive Cancer Center study (NCT07639242) tests first-line olomorasib plus pembrolizumab in locally advanced/metastatic NSCLC with a KRAS G12C mutation and PD-L1 TPS 1–49%. Olomorasib (Eli…
NCT07639242 Exploratory - New trial
Non-small cell lung cancer
Phase 2 PF-08634404 trial tests PD-1×VEGF bispecific antibody in stage II–III NSCLC
This open-label Phase 2 Pfizer study (NCT07489066) evaluates PF-08634404—an investigational bispecific antibody that targets PD-1 (to relieve T-cell inhibition) and VEGF/VEGF-A (to reduce pro-angiogenic,…
NCT07489066 Exploratory - New trial Spotlight
Kidney cancer
Phase 3 belzutifan HIF-2α inhibitor + zanzalintinib MET/VEGFR TKI vs cabozantinib
Merck Sharp & Dohme (MSD) is running LITESPARK-033 (MK-6482-033), a Phase 3, randomized, open-label, multicenter study in recurrent advanced clear cell RCC after prior adjuvant anti–PD-1/PD-L1 therapy. Participants…
NCT07227402 Registrational - New trial Spotlight
Breast cancer
Phase 3 BGB-43395 CDK4-selective inhibitor plus letrozole vs CDK4/6 inhibitors in 1L HR+/HER2- MBC
This open-label, randomized, multicenter Phase 3 study (BeOne Medicines) tests whether BGB-43395—an oral, CDK4-selective small-molecule inhibitor—combined with letrozole (aromatase inhibitor) improves outcomes versus…
NCT07492641 Registrational - New trial
Colorectal cancer
Phase 2 denikitug (GS-1811) trial tests CCR8-targeted Treg-depleting antibody in MSS CRC.
This Phase 2, open-label, multicenter, randomized study from Gilead Sciences evaluates denikitug (GS-1811), a CCR8-directed monoclonal antibody designed to target CCR8-expressing tumor-infiltrating regulatory T cells…
NCT07527858 Exploratory - New trial
Head and neck cancer
Pilot (early feasibility) ConformalFLASH ultra-high–dose-rate proton therapy (FLASH radiotherapy) for HNSCC reirradiation
This pilot interventional study (C-FLASH-01) evaluates whether ultra-high dose-rate conformal proton therapy (ConformalFLASH®) can be planned and delivered safely and reproducibly for patients who need head and neck…
NCT07644585 Exploratory - New trial
Sarcoma and GIST
Phase 2 eflornithine (DFMO) ornithine decarboxylase inhibitor added/maintenance in Ewing and osteosarcoma
This Phase 2, non-randomized, open-label basket study tests eflornithine (DFMO)—a small-molecule ornithine decarboxylase (ODC) inhibitor that suppresses polyamine synthesis—as concurrent therapy with multi-agent…
NCT07321912 Exploratory - New trial
Multiple solid tumors
Phase 1 BSI-082 anti-SIRPα macrophage checkpoint antibody ± T-DXd HER2 ADC
This open-label Phase 1a/1b, two-part dose-escalation and dose-expansion study evaluates BSI-082 (a fully human anti–SIRPα monoclonal antibody that blocks the CD47–SIRPα “don’t eat me” signal to enhance…
NCT07086768 First-in-human - New trial
Multiple solid tumors
Phase 1/2 PM54 + pembrolizumab tests tubulin (microtubule) inhibition paired with PD-1 blockade.
This multicenter, open-label Phase 1/2 trial from PharmaMar evaluates PM54 (a small-molecule microtubule/tubulin inhibitor) combined with pembrolizumab (Keytruda; Merck/MSD’s PD-1–blocking monoclonal antibody) in…
NCT07644039 Exploratory - New trial
Multiple solid tumors
Phase 1/2 VMD-102 selective PKCε (protein kinase C epsilon) inhibitor in HCC and solid tumors.
This first-in-human, open-label, multicenter Phase 1/2 study sponsored by VM Discovery evaluates VMD-102, a selective PKC epsilon (PKCε) kinase inhibitor intended to suppress oncogenic PKC signaling that can promote…
NCT07636785 First-in-human - New trial
Multiple solid tumors
Phase 1 MSK‑TCR5 CD8α/β‑armored KRAS/HRAS/NRAS G12D TCR‑T therapy
This Memorial Sloan Kettering Cancer Center (MSKCC) investigator-initiated Phase 1, open-label, dose-escalation trial tests MSK‑TCR5—an autologous T‑cell receptor–engineered T‑cell product designed to recognize the…
NCT07638371 First-in-human - Trial result Spotlight
Breast cancer
T-DXd (HER2 ADC) + durvalumab (PD-L1) delivers ~83% ORR and ~38-month mPFS in 1L HER2+ mBC
Trastuzumab deruxtecan (T-DXd) is a HER2-targeted antibody–drug conjugate (topoisomerase I payload), combined here with durvalumab, an anti–PD-L1 antibody, as first-line therapy in the DESTINY-Breast07 Phase 1b/2…
NCT04538742 - Trial result Spotlight
Breast cancer
T-DXd (HER2 ADC) + pertuzumab: CRs deepen slowly (8.4mo) but track with NC PFS in 1L HER2+ mBC
Trastuzumab deruxtecan (T-DXd) is a HER2-directed antibody–drug conjugate (topoisomerase I payload) combined with pertuzumab (HER2 dimerization-blocking mAb) in the Phase 3 DESTINY-Breast09 first-line setting…
NCT04784715 - Trial result Spotlight
Breast cancer
Giredestrant (oral SERD/full ER antagonist) cuts recurrence risk in ER+/HER2– early breast cancer—benefit holds in pre- and postmenopause
Giredestrant (GIRE) is a next-generation oral selective estrogen receptor degrader (SERD) and full ER antagonist tested as 5-year adjuvant endocrine therapy in the global, randomized Phase III lidERA BC trial…
NCT04961996 - Trial result Spotlight
Breast cancer
Tucatinib (HER2 TKI) + trastuzumab/pertuzumab extends PFS as 1L HER2+ MBC maintenance—benefit holds across HR/BM subgroups
Tucatinib (TUC), an oral HER2-selective tyrosine kinase inhibitor, was evaluated in the Phase 3 HER2CLIMB-05 maintenance trial (NCT05132582) after induction taxane + trastuzumab/pertuzumab (HP) in HER2+ metastatic…
NCT05132582 - Trial result Spotlight
Breast cancer
Intratumoral DC1 (type 1 dendritic cell) immunotherapy + dual HER2 blockade drives 89% pCR in HR−/HER2+ early breast cancer
IT DC1 is an intratumoral conventional type 1 dendritic-cell (cDC1/DC1) therapy intended to inflame the tumor microenvironment; in the single-arm Phase 2 NATASHA trial (NCT05325632), patients with stage I–III HER2+…
NCT05325632 - Trial result Spotlight
Breast cancer
Dato-DXd (TROP2 ADC) extends PFS2/TFST/TSST vs chemo in 1L IO-ineligible metastatic TNBC
Datopotamab deruxtecan (Dato-DXd) is a TROP2-directed antibody–drug conjugate delivering a topoisomerase I inhibitor payload (deruxtecan); in the Phase 3, open-label TROPION-Breast02 trial (NCT05374512), previously…
NCT05374512 - Trial result Spotlight
Breast cancer
Sacituzumab govitecan (TROP2 ADC) + pembrolizumab extends PFS vs chemo+pembro across TROP2, tBRCA, and HER2-low mTNBC subgroups
Sacituzumab govitecan (SG) is a TROP2-directed antibody–drug conjugate delivering SN-38, combined here with pembrolizumab (PD-1 inhibitor) as first-line therapy in the Phase 3 ASCENT-04/KEYNOTE-D19 trial…
NCT05382286 - Trial result Spotlight
Breast cancer
ZN-A-1041 (BBB-permeable HER2 TKI) + T-DXd drives 65%–76% ORR in HER2+ mBC (incl CNS mets)
ZN-A-1041 is an oral, selective HER2 tyrosine kinase inhibitor designed for high intact blood–brain barrier permeability; in the Phase Ic ZN-A-1041-101-US trial (NCT05593094), it was combined with trastuzumab…
NCT05593094 - Trial result Spotlight
Breast cancer
Gedatolisib (pan-PI3K/mTORC1/2 inhibitor) + fulvestrant ± palbociclib doubles PFS vs alpelisib in PIK3CA-mut HR+/HER2− ABC
Gedatolisib (IV, comprehensive PI3Kα/β/δ/γ + mTORC1/2 inhibitor) was tested in the randomized, open-label Phase 3 VIKTORIA-1 Study 2 (NCT05501886) in HR+/HER2− PIK3CA-mutant advanced breast cancer after progression…
NCT05501886 - Trial result
Breast cancer
Cavity shave margins (CSM) cut positive margins/re-excisions but do not improve DFS or OS at ~5 years in Stage 0–III breast cancer (SHAVE + SHAVE2 pooled).
In the pooled SHAVE (single-center) and SHAVE2 (9-site US) randomized trials (n=631; Stage 0–III planned partial mastectomy; median follow-up 60.4 months), patients were intraoperatively randomized after standard…
NCT01452399 - Trial result
Breast cancer
Pembrolizumab (PD-1) added to neoadjuvant THP trends toward higher 3-year EFS in stage II–III HER2+ breast cancer
In the randomized Phase 2 neoHIP trial (NCT03747120), patients with stage II–III HER2-positive breast cancer received neoadjuvant paclitaxel + trastuzumab + pertuzumab (THP) with or without pembrolizumab (an…
NCT03747120 - Trial result
Breast cancer
Durvalumab (PD-L1) + paclitaxel posts ~56% ORR in 1L mTNBC; capivasertib (AKT) or oleclumab (CD73) add little
Durvalumab is an anti–PD-L1 monoclonal antibody combined here with weekly paclitaxel chemotherapy, with exploratory triplets adding capivasertib (a pan-AKT inhibitor) or oleclumab (an anti-CD73 adenosine-pathway…
NCT03742102 - Trial result
Breast cancer
HER2-targeted trastuzumab shows “on-time” benefit but late RFS drop-off in HER2+ lobular breast cancer
Trastuzumab (anti-HER2 monoclonal antibody) outcomes were dissected by histology in the Phase III adjuvant NCCTG N9831 trial (NCT00005970), comparing HER2+ invasive lobular carcinoma (ILC; n=122) vs invasive ductal…
NCT00005970
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.